Acoramidis
A small molecule medication that stabilizes the transthyretin protein, preventing it from misfolding and clumping into harmful amyloid deposits in the heart and nerves. It is used to treat transthyretin amyloid cardiomyopathy, a progressive condition in which amyloid buildup weakens and stiffens the heart muscle. Taken orally three times daily, it has been shown to slow the progression of the disease and reduce hospitalizations for heart failure.
Peso molecular
292,3000 g/mol
LogP
2,90
TPSA
75,20 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F
InChI
InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)
Molecular Formula
C15H17FN2O3
HBD / HBA
2 / 5
Enlaces Rotables
6
Átomos Pesados
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A small molecule medication that stabilizes the transthyretin protein, preventing it from misfolding and clumping into harmful amyloid deposits in the heart and nerves. It is used to treat transthyretin amyloid cardiomyopathy, a progressive condition in which amyloid buildup weakens and stiffens the heart muscle. Taken orally three times daily, it has been shown to slow the progression of the disease and reduce hospitalizations for heart failure.
Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.
Yes, Acoramidis is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3940890. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71464713. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acoramidis"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acoramidis/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acoramidis/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acoramidis/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acoramidis"></drugfyi-drug>